BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play

Reuters02-04 21:59

BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play

** Amgen AMGN.O on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations and the company continues to express confidence in experimental weight-loss drug MariTide

** At least six brokerages raise PT on the stock following results

VOLUME GROWTH A KEY DRIVER

** Morgan Stanley ("equal weight," PT: $309) says new launches and pipeline progress remain the "focus on the forward" for the stock

** William Blair ("outperform") says "MariTide still a major focus but we still think not much new to debate until Phase III results in 2027"

** TD Cowen ("buy," PT: $420) says volume would be a key driver into FY26 and beyond** "Competitive pricing appears to be securing favorable formulary positions and driving broad usage, a dynamic we expect to persist" - TD Cowen

** RBC Capital Markets ("outperform," PT: $360) says "overall, we continue to like a highly diversified business and an impressive track record of commercial execution, but we are also eager to see additional data for MariTide to better understand where AMGN can fit in the broader competitive landscape for obesity"

(Reporting by Joel Jose in Bengaluru)

((joeljose@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608367664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608367664","market":"fut","top_or_hot":-1,"title":"BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play</title></head><body><p>** Amgen <span>AMGN.O</span> on Tuesday <span>reported</span> fourth-quarter financial results that came in ahead of Wall Street expectations and the company continues to express confidence in experimental weight-loss drug MariTide</p><p>** At least six brokerages raise PT on the stock following results</p><p>VOLUME GROWTH A KEY DRIVER</p><p>** <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a> (\"equal weight,\" PT: $309) says new launches and pipeline progress remain the \"focus on the forward\" for the stock</p><p>** William Blair (\"outperform\") says \"MariTide still a major focus but we still think not much new to debate until Phase III results in 2027\"</p><p>** TD Cowen (\"buy,\" PT: $420) says volume would be a key driver into FY26 and beyond** \"Competitive pricing appears to be securing favorable formulary positions and driving broad usage, a dynamic we expect to persist\" - TD Cowen</p><p>** RBC Capital Markets (\"outperform,\" PT: $360) says \"overall, we continue to like a highly diversified business and an impressive track record of commercial execution, but we are also eager to see additional data for MariTide to better understand where AMGN can fit in the broader competitive landscape for obesity\"</p><p> (Reporting by Joel Jose in Bengaluru)</p><p> ((joeljose@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 21:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play</title></head><body><p>** Amgen <span>AMGN.O</span> on Tuesday <span>reported</span> fourth-quarter financial results that came in ahead of Wall Street expectations and the company continues to express confidence in experimental weight-loss drug MariTide</p><p>** At least six brokerages raise PT on the stock following results</p><p>VOLUME GROWTH A KEY DRIVER</p><p>** <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a> (\"equal weight,\" PT: $309) says new launches and pipeline progress remain the \"focus on the forward\" for the stock</p><p>** William Blair (\"outperform\") says \"MariTide still a major focus but we still think not much new to debate until Phase III results in 2027\"</p><p>** TD Cowen (\"buy,\" PT: $420) says volume would be a key driver into FY26 and beyond** \"Competitive pricing appears to be securing favorable formulary positions and driving broad usage, a dynamic we expect to persist\" - TD Cowen</p><p>** RBC Capital Markets (\"outperform,\" PT: $360) says \"overall, we continue to like a highly diversified business and an impressive track record of commercial execution, but we are also eager to see additional data for MariTide to better understand where AMGN can fit in the broader competitive landscape for obesity\"</p><p> (Reporting by Joel Jose in Bengaluru)</p><p> ((joeljose@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL4N3Z018I:1","article_id":"2608367664","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608367664","pubTimestamp":1770213581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play** Amgen AMGN.O on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations and the company continues to express confidence in experimental weight-loss drug MariTide** At least six brokerages raise PT on the stock following resultsVOLUME GROWTH A KEY DRIVER** Morgan Stanley  says new launches and pipeline progress remain the \"focus on the forward\" for the stock** William Blair  says \"MariTide still a major focus but we still think not much new to debate until Phase III results in 2027\"** TD Cowen  says volume would be a key driver into FY26 and beyond** \"Competitive pricing appears to be securing favorable formulary positions and driving broad usage, a dynamic we expect to persist\" - TD Cowen** RBC Capital Markets  says \"overall, we continue to like a highly diversified business and an impressive track record of commercial execution, but we are also eager to see additio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","AMGN":"安进","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4566":"资本集团","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"BUZZ-Street View：安进依靠管道深度和长期减肥计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":0.9},"content_text":"BUZZ-Street View: Amgen banks on pipeline depth and long term weight-loss play** Amgen AMGN.O on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations and the company continues to express confidence in experimental weight-loss drug MariTide** At least six brokerages raise PT on the stock following resultsVOLUME GROWTH A KEY DRIVER** Morgan Stanley (\"equal weight,\" PT: $309) says new launches and pipeline progress remain the \"focus on the forward\" for the stock** William Blair (\"outperform\") says \"MariTide still a major focus but we still think not much new to debate until Phase III results in 2027\"** TD Cowen (\"buy,\" PT: $420) says volume would be a key driver into FY26 and beyond** \"Competitive pricing appears to be securing favorable formulary positions and driving broad usage, a dynamic we expect to persist\" - TD Cowen** RBC Capital Markets (\"outperform,\" PT: $360) says \"overall, we continue to like a highly diversified business and an impressive track record of commercial execution, but we are also eager to see additional data for MariTide to better understand where AMGN can fit in the broader competitive landscape for obesity\" (Reporting by Joel Jose in Bengaluru) ((joeljose@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608367664","isCrawlerRequest":true}